Report

src

Depression Drugs Market By Type (Selective Serotonin Reuptake Inhibitors, Serotonin and Norepinephrine Reuptake Inhibitors, Dopamine Reuptake Blocker, Tetracyclic Antidepressant, Tricyclic Antidepressants, Others) By End-use (Major Depressive Disorder, Schizophrenia and Bipolar Disorder, Obsessive-Compulsive Disorders, Anxiety Disorder, and Others) Market - Growth, Future Prospects, Post COVID-19 Scenario, 2020 - 2028

Depression can be defined as mood disorder with a feeling of sadness, loss, or anger that interferes with a person’s day-to-day activities. It results from a complex interaction of social, psychological and biological factors. Depression can be of various types and people experience it in different ways. It may interfere with an individual's daily work that results in lost time and lower productivity. It can also influence personal relationships and can cause some chronic health conditions. Major symptoms associated with depression have a tremendous impact on one’s emotional and physical well-being. It causes insomnia, fatigue, lack of sexual performance, loss of interest, hopeless, etc. Depending on the number and severity of symptoms, a depressive episode can be categorized as mild, moderate or severe. With technological and scientific advancements in the pharmaceutical industry, there has been effective treatments for moderate and severe depression. Doctors recommend psychological treatments such as behavioral activation, cognitive behavioral therapy (CBT) and interpersonal psychotherapy (IPT), or antidepressant medication. Common antidepressants help to ease symptoms associated with depression. These drugs works on mechanism of balancing certain chemicals in brain known as neurotransmitters. It inhibits reuptake of neurotransmitters through selective receptors thereby, increasing the concentration of specific neurotransmitters around the nerves in the brain thereby, curbing symptoms of depression.
 
There are various medications for the treatment of depression, which include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRI), dopamine reuptake blocker, tetracyclic antidepressant, tricyclic antidepressants, and others. These drugs are used to treat various conditions such as major depressive disorder, schizophrenia and bipolar disorder, obsessive-compulsive disorders, anxiety disorder, among other disorders. According to WHO, depression is one of the most common mental disorders. Globally, more than 264 million people of all ages suffer from depression. It also leads to suicidal thoughts and it is estimated that approximately 800,000 people die due to suicide every year. This is one of the major factors responsible for the growth of antidepressants drugs market. Factors such as increasing stress level, consumption of alcohol and tobacco, changing lifestyle, work life imbalance, and social alienation causes mild to severe depression. Thus, all these factors boost antidepressant drugs market growth across the globe. Furthermore, surging geriatric population on a global scale especially in developed countries enhances use of antidepressants drugs. In addition, research and development activities for the advancement in neurobiology of depression over the past few years will create lucrative opportunities in following years. In addition, the out-burst of the COVID-19 pandemic has resulted in growing concerns as large number of people across the globe are suffering from mental health conditions. Thereby, there has been a rise in the prescription of antidepressant drugs since 2020.
 
Key players involved in antidepressant drugs market are adopting expansion strategies through new product development, mergers, and acquisitions. Major players involved in depression drugs market are Allergan, Plc, Novartis International AG, Lupin Pharmaceuticals, Inc., Abbott Laboratories, Johnson & Johnson Services, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, and Pfizer, Inc.

Global Depression Drugs Market, By Type
Based on type, the depression drugs market is segmented into the following:
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)
  • Dopamine Reuptake Blocker
  • Tetracyclic Antidepressant
  • Tricyclic Antidepressants
  • Others
Below graph provides a comparative analysis of the value contribution for each of the segment for the years 2019 and 2028:

Global Depression Drugs Market Value Share, By Type, 2019 & 2028(% Value)


In 2019, selective serotonin reuptake inhibitors (SSRIs) segment led the overall depression drugs market in terms of market value accounting for approximately 24% of the global market, as they are most commonly prescribed class of antidepressants. Imbalance of serotonin plays a major role in depression. Serotonin is a neurotransmitter that is present in the gut and in the brain. In the brain, low levels of serotonin have been associated with depression and anxiety as well as panic disorders and obsessive-compulsive behavior. They prevent reuptake of serotonin, thereby, enabling higher availability of serotonin in order to regulate mood. SSRI drugs include Prozac, Zoloft, Lexapro, and Paxil. However, serotonin-norepinephrine reuptake inhibitor (SNRI) will show high growth rate in following years due to its dual mechanism of action. It increases neurotransmitters serotonin and norepinephrine by inhibiting their reabsorption into cells in the brain. In addition to treating depression, some of the drugs in this category can also be used to relieve pain.
 
Global Depression Drugs Market, By End-use
Based on end-use, the depression drugs market is segmented into following:
  • Major Depressive Disorder
  • Schizophrenia and Bipolar Disorder
  • Obsessive-Compulsive Disorders
  • Anxiety Disorder
  • Others
Below graph provides a comparative analysis of the value contribution for each of the segment for the years 2019 and 2028:

Global Depression Drugs Market Value Share, By End-use, 2019 & 2028(% Value)


In 2019, major depressive disorder segment led the overall depression drugs market in terms of market value. This can be attributed as it is the most commonly diagnosed type of depression. It was estimated that about 6.7% of American adults, have had at least one major depressive episode in a given year. It affects the mood and behavior of a person along with various physical functions, such as appetite and sleep. It is caused due to psychiatric issues or genetic factors. In 2018, a genome-wide association study discovered 44 variants in the genome linked to risk for major depression. This was tracked by a 2019 study that found 102 variants in the genome linked to depression.
 
Global Depression Drugs Market, By Geography
Based on geography, the depression drugs market is segmented into following:
  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA
Below graph provides a comparative analysis of the value contribution for each of the segment for the years 2019 and 2028:

Global Depression Drugs Market Value Share, By Geography, 2019 & 2028(% Value)


In 2019, North America held the largest share in the depression drugs market. This can be attributed due to rising average number of people suffering from depression in U.S. In 2017, an estimated 11 million U.S. adults aged 18 or older had at least one major depressive episode with severe impairment. More than 1 in 6 Americans take a psychiatric drug (such as an antidepressant or a sedative). Additionally, number of females suffering from distress before and after the pregnancies in US is rising. However, Asia Pacific region will propel significant rise in following years. Prevalence of depression rates have increased in some countries such as China, India, Japan, Korea, Thailand and Malaysia, among others. Japan shows significant rise in antidepressants market due to large aging population in this region. Additionally, rising awareness regarding mental health in these regions have significantly boost depression drugs market.
Table of Content

Chapter 1    Preface
    1.1    Report Description
        1.1.1    Aim of the Report
        1.1.2    Report Target Audience
        1.1.3    Report Offering
    1.2    Research Scope
    1.3    Research Methodology
        1.3.1    Phase I – Secondary Research
        1.3.2    Phase II – Primary Research
        1.3.3    Phase III – Expert Panel Review
        1.3.4    Assumptions
        1.3.5    Top-Down and Bottom-Up Approach
Chapter 2    Executive Summary
    2.1    Market Snapshot: Global Depression Drugs
    2.2    Global Depression Drugs, By Product Type
    2.3    Global Depression Drugs, By End-user
    2.4    Global Depression Drugs, By Geography
Chapter 3    Market Dynamics
    3.1    Product Type and Market Insights
        3.1.1    Global Depression Drugs Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
    3.2    Market Dynamics
        3.2.1    Growth Drivers
        3.2.2    Market Restraints
        3.2.3    Impact Analysis of Drivers and Restraints
        3.2.4    Trends and Future Outlook
    3.3    Attractive Investment Proposition
    3.4    Competitive Analysis
        3.4.1    Competitive Landscape in the Depression Drugs
Chapter 4    Global Depression Drugs Market Analysis, By Product Type
    4.1    Overview
    4.2    Selective Serotonin Reuptake Inhibitors (SSRIs)
        4.2.1    Global Selective Serotonin Reuptake Inhibitors (SSRIs) Depression Drugs Value, 2018 – 2028, (US$ Mn)
    4.3    Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)
        4.3.1    Global Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Depression Drugs Value, 2018 – 2028, (US$ Mn)
    4.4    Dopamine Reuptake Blocker
        4.4.1    Global Dopamine Reuptake Blocker Depression Drugs Value, 2018 – 2028, (US$ Mn)
    4.5    Tetracyclic Antidepressant
        4.5.1    Global Tetracyclic Antidepressant Depression Drugs Value, 2018 – 2028, (US$ Mn)
    4.6    Tricyclic Antidepressants
        4.6.1    Global Tricyclic Antidepressants Depression Drugs Value, 2018 – 2028, (US$ Mn)
    4.7    Others
        4.7.1    Global Other Drugs Value, 2018 – 2028, (US$ Mn)
Chapter 5    Global Depression Drugs Market Analysis, By End-user
    5.1    Overview
    5.2    Major Depressive Disorder
        5.2.1    Global Depression Drugs Value for Major Depressive Disorder, 2018 – 2028, (US$ Mn)
    5.3    Schizophrenia and Bipolar Disorder
        5.3.1    Global Depression Drugs Value for Schizophrenia and Bipolar Disorder, 2018 – 2028, (US$ Mn)
    5.4    Obsessive-Compulsive Disorders
        5.4.1    Global Depression Drugs Value for Obsessive-Compulsive Disorders, 2018 – 2028, (US$ Mn)
    5.5    Anxiety Disorder
        5.5.1    Global Depression Drugs Value for Anxiety Disorder, 2018 – 2028, (US$ Mn)
    5.6    Others
        5.6.1    Global Depression Drugs Value for Others, 2018 – 2028, (US$ Mn)
Chapter 6    North America Depression Drugs Market Analysis
    6.1    Overview
    6.2    North America Depression Drugs Market Analysis, By Product Type, 2018 – 2028
        6.2.1    Market Analysis
    6.3    North America Depression Drugs Market Analysis, By End-user, 2018 – 2028
        6.3.1    Market Analysis
    6.4    North America Depression Drugs Market Analysis, By Country, 2018 – 2028
        6.4.1    Market Analysis
        6.4.2    U.S.
        6.4.3    Canada
Chapter 7    Europe Depression Drugs Market Analysis
    7.1    Overview
    7.2    Europe Depression Drugs Market Analysis, By Product Type, 2018 – 2028
        7.2.1    Market Analysis
    7.3    Europe Depression Drugs Market Analysis, By End-user, 2018 – 2028
        7.3.1    Market Analysis
    7.4    Europe Depression Drugs Market Analysis, By Country, 2018 – 2028
        7.4.1    Market Analysis
        7.4.2    UK
        7.4.3    Germany
        7.4.4    France
        7.4.5    Rest of Europe
Chapter 8    Asia Pacific Depression Drugs Market Analysis
    8.1    Overview
    8.2    Asia Pacific Depression Drugs Market Analysis, By Product Type, 2018 – 2028
        8.2.1    Market Analysis
    8.3    Asia Pacific Depression Drugs Market Analysis, By End-user, 2018 – 2028
        8.3.1    Market Analysis
    8.4    Asia Pacific Depression Drugs Market Analysis, By Country, 2018 – 2028
        8.4.1    Market Analysis
        8.4.2    China
        8.4.3    Japan
        8.4.4    India
        8.4.5    Rest of Asia Pacific
Chapter 9    Latin America Depression Drugs Market Analysis
    9.1    Overview
    9.2    Latin America Depression Drugs Market Analysis, By Product Type, 2018 – 2028
        9.2.1    Market Analysis
    9.3    Latin America Depression Drugs Market Analysis, By End-user, 2018 – 2028
        9.3.1    Market Analysis
    9.4    Latin America Depression Drugs Market Analysis, By Country, 2018 – 2028
        9.4.1    Market Analysis
        9.4.2    Mexico
        9.4.3    Brazil
        9.4.4    Rest of Latin America
Chapter 10    Middle East and Africa (MEA) Depression Drugs Market Analysis
    10.1    Overview
    10.2    MEA Depression Drugs Market Analysis, By Product Type, 2018 – 2028
        10.2.1    Market Analysis
    10.3    MEA Depression Drugs Market Analysis, By End-user, 2018 – 2028
        10.3.1    Market Analysis
    10.4    MEA Depression Drugs Market Analysis, By Country, 2018 – 2028
        10.4.1    Market Analysis
        10.4.2    GCC Countries
        10.4.3    South Africa
        10.4.4    Rest of MEA
Chapter 11    Company Profiles
    11.1    Allergan, Plc
        11.1.1    Allergan, Plc: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    11.2    Novartis International AG
        11.2.1    Novartis International AG: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    11.3    Lupin Pharmaceuticals, Inc.
        11.3.1    Lupin Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    11.4    Abbott Laboratories
        11.4.1    Abbott Laboratories: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    11.5    Johnson & Johnson Services, Inc.
        11.5.1    Johnson & Johnson Services, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and         Announcements)
    11.6    Otsuka Pharmaceutical Co., Ltd.
        11.6.1    Otsuka Pharmaceutical Co., Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    11.7    Eli Lilly and Company
        11.7.1    Eli Lilly and Company: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    11.8    Takeda Pharmaceutical Company Limited
        11.8.1    Takeda Pharmaceutical Company Limited: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    11.9    GlaxoSmithKline Plc
        11.9.1    GlaxoSmithKline Plc: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    11.10    Pfizer, Inc.
        11.10.1    Pfizer, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)

List of Figures 
    FIG. 1 Global Depression Drugs: Research Methodology
    FIG. 2 Top-Down and Bottom Up Approach
    FIG. 3 Global Depression Drugs, By Product Type, 2019 (US$ Mn)
    FIG. 4 Global Depression Drugs, By End-user, 2019 (US$ Mn)
    FIG. 5 Global Depression Drugs, By Geography, 2019 (US$ Mn)
    FIG. 6 Global Depression Drugs Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
    FIG. 7 Attractive Investment Proposition
    FIG. 8 Market Positioning of Key Nutricosmetics Providers, 2019
    FIG. 9 Global Depression Drugs Value Share, By Product Type, 2019 & 2028 (% Value)
    FIG. 10 Global Selective Serotonin Reuptake Inhibitors (SSRIs) Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 1 Global Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 2 Global Dopamine Reuptake Blocker Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 3 Global Tetracyclic Antidepressant Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 4 Global Tricyclic Antidepressants Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 5 Global Other Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 6 Global Depression Drugs Value Share, By End-user, 2019 & 2028 (% Value)
    FIG. 7 Global Depression Drugs Value for Major Depressive Disorder, 2018 – 2028, (US$ Mn)
    FIG. 8 Global Depression Drugs Value for Schizophrenia and Bipolar Disorder, 2018 – 2028, (US$ Mn)
    FIG. 9 Global Depression Drugs Value for Obsessive-Compulsive Disorders, 2018 – 2028, (US$ Mn)
    FIG. 10 Global Depression Drugs Value for Anxiety Disorder, 2018 – 2028, (US$ Mn)
    FIG. 11 Global Depression Drugs Value for Others, 2018 – 2028, (US$ Mn)
    FIG. 12 U.S. Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 13 Canada Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 14 UK Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 15 Germany Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 16 France Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 17 Rest of Europe Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 18 China Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 19 Japan Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 20 India Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 21 Rest of Asia Pacific Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 22 Mexico Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 23 Brazil Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 24 Rest of Latin America Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 25 GCC Countries Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 26 South Africa Depression Drugs Value, 2018 – 2028, (US$ Mn)
    FIG. 27 Rest of MEA Depression Drugs Value, 2018 – 2028, (US$ Mn)


List of Tables
    TABLE 1 Market Snapshot: Global Depression Drugs
    TABLE 2 Impact Pointers
    TABLE 3 Impact Analysis of Drivers and Restraints
    TABLE 4 North America Depression Drugs Value, By Product Type, 2018 – 2028
    TABLE 5 North America Depression Drugs Value, By End-user, 2018 – 2028
    TABLE 6 North America Depression Drugs Value, By Country, 2018 – 2028
    TABLE 7 Europe Depression Drugs Value, By Product Type, 2018 – 2028
    TABLE 8 Europe Depression Drugs Value, By End-user, 2018 – 2028
    TABLE 9 Europe Depression Drugs Value, By Country, 2018 – 2028
    TABLE 10 Asia Pacific Depression Drugs Value, By Product Type, 2018 – 2028
    TABLE 11 Asia Pacific Depression Drugs Value, By End-user, 2018 – 2028
    TABLE 12 Asia Pacific Depression Drugs Value, By Country, 2018 – 2028
    TABLE 13 Latin America Depression Drugs Value, By Product Type, 2018 – 2028
    TABLE 14 Latin America Depression Drugs Value, By End-user, 2018 – 2028
    TABLE 15 Latin America Depression Drugs Value, By Country, 2018 – 2028
    TABLE 16 MEA Depression Drugs Value, By Product Type, 2018 – 2028
    TABLE 17 MEA Depression Drugs Value, By End-user, 2018 – 2028
    TABLE 18 MEA Depression Drugs Value, By Country, 2018 – 2028
    TABLE 19 Allergan, Plc: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    TABLE 20 Novartis International AG: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    TABLE 21 Lupin Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    TABLE 22 Abbott Laboratories: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    TABLE 23 Johnson & Johnson Services, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    TABLE 24 Otsuka Pharmaceutical Co., Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    TABLE 25 Eli Lilly and Company: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    TABLE 26 Takeda Pharmaceutical Company Limited: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    TABLE 27 GlaxoSmithKline Plc: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
    TABLE 28 Pfizer, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Type Portfolio, Recent News and Announcements)
No Methodology
No Available